Artivila (Shenzhen) Innovation Center Ltd. has identified NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, multiple sclerosis, amyotrophic lateral sclerosis and peripheral neuropathy.

Xi’an Xintong Medicine Research Co. Ltd. has synthesized tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis, alopecia areata, vitiligo, asthma, chronic obstructive pulmonary disease, cancer and inflammatory bowel disease.

Genzyme Corp. (Sanofi Genzyme) has disclosed sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, among others.

Researchers at Viva Star Biosciences (Suzhou) Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.

Silexon Intelligent Technology Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.

Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.

Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis.

Ohio State University has described NADH-ubiquinone oxidoreductase (complex I) inhibitors acting as radiosensitizers for radiation therapy reported to be useful for the treatment of cancer.

Forschungsverbund Berlin eV has divulged phosphatidylinositol 4-phosphate 3-kinase (PI3K) inhibitors, particularly PI3K C2 domain-containing subunit β (PIK3C2B) inhibitors, reported to be useful for the treatment of cancer, diabetes, X-linked myotubular myopathy and cardiovascular disorders.